3D Mapping and Navigation System to Improve outcome of the Renal Denervation Therapy
Our mission is to improve the management of non-responders and enhance the outcomes of the renal denervation procedure
What is Renal Denervation?
A new approach for the management of the arterial hypertension
Arterial hypertension
Hypertension is a major cause of premature death and the main risk factor for stroke, myocardial infarction, heart and kidney failure and vision loss.
- 1.4 billion adults worldwide have hypertension
- Patients must take medications daily
- 10% of patients have resistant hypertension
Renal Denervation
Renal Denervation is a novel method for the treatment of hypertension. This is a minimally invasive endovascular catheter procedure for ablation of the the sympathetic nerves of the kidneys surrounding the renal arteries.
- Effective
- Save
- Minimal Invasive
Problem of non-responders
Renal Denervation has proven to be safe. Catheters for procedure were approved in USA. However the therapy has a problem of non-responders.
- 35% of non-responders
- Problem of non-responsder stops adoptation of the technology
- No solution on the market
ReNavie Sensing 3D Mapping and Navigation
Our mission is significantly improve clinical outcome of the renal denervation procedure by providing a tool for systematic control of the ablation process.
Selective Ablation of Sympathetic Nerves
A method that ablates only sympathetic nerves while avoiding parasympathetic nerves.
Real-Time 3D Mapping and Navigation
Visualization of the renal anatomy along with the real-time position of the ablation catheter.
Highlighting the Sympathetic Ganglia
Addresses the issue of non-responders by correctly identifying the target areas for ablation.
Comprehensive Impedance Mapping
Provides precise response from electrical pacing to better control the outcome of the ablation procedure.
3D Mapping and Navigation
Sympathetic nerves selectivity
Renal Denervation Systems
Recieved FDA approval
Now the Renal Denervation is a part of 2003 ESH Guidelines for the management of arterial hypertension
ESH Guidelines recommend renal denervation as Class II for uncontrolled hypertension patients.
European Society of Cardiology recommends renal denervation as an evidence-based treatment option for uncontrolled resistant hypertension.
Based on data from the National Health and Nutrition Examination Survey (NHANES) (2009–2020), an estimated 21.5% of U.S. adults with hypertension would qualify for RDN under FDA indications.